HB0017
Phase 2Small molecule
HB0017 is one of 31 small molecule programs targeting Psoriasis. It is currently in Phase 2.
1
Indications
4
Total Trials
2
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
605 competitors in Psoriasis
#DrugCompanyPhaseTrials
1Stelara
Johnson & JohnsonPreclinical
Taltz
Eli LillyPreclinical
Bimzelx
UCBPreclinical
Humira
CCelltrion
Preclinical
Ilumya
Sun Pharmaceutical Industries, Inc.Preclinical
Raptiva
RochePreclinical
Remicade
OOrganon and Co
Preclinical
Siliq
BBausch Health Americas, Inc.
Preclinical
Lovenox
SanofiPreclinical
Olux
HHarrow Inc
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Psoriasis3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HB0017. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- HHuabo Biopharm Co., Ltd.